It was the Annual Report. As the name suggests, it’s a report of the year that’s been. The company still has potential. We are in a TH now which I expect the outcome of the independent assessment to be announced in due course. A cash neutral redesigned trial for IIH with a 6-12 month delay would be acceptable for me. If the trial is not to be redesigned I’ll be wanting to know the next step. I assume funds will be redirected to pursuing TBI.
IXC Price at posting:
18.0¢ Sentiment: Hold Disclosure: Held
